Israel Englander Alpine Immune Sciences, Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $4.59 Million - $10.8 Million	-258,628 Reduced 94.71%	14,438 $572,000
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $1.34 Million - $3.17 Million	156,891 Added 135.05%	273,066 $5.2 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $794,637 - $1.38 Million	116,175 New	116,175 $1.19 Million
Q2 2021 Aug 16, 2021	SELL	$8.81 - $15.03 $845,909 - $1.44 Million	-96,017 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$10.02 - $13.92 $503,464 - $699,424	50,246 Added 109.78%	96,017 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$7.42 - $15.96 $2,129 - $4,580	-287 Reduced 0.62%	45,771 $577,000
Q3 2020 Nov 16, 2020	BUY	$7.15 - $11.5 $329,314 - $529,667	46,058 New	46,058 $405,000
Q4 2018 Feb 14, 2019	SELL	$3.68 - $6.07 $39,353 - $64,912	-10,694 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.68 - $8.59 $60,741 - $91,861	10,694 New	10,694 $68,000
Q2 2018 Aug 14, 2018	SELL	$7.16 - $10.05 $98,127 - $137,735	-13,705 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$7.95 - $11.65 $36,307 - $53,205	-4,567 Reduced 24.99%	13,705 $110,000
Q4 2017 Feb 14, 2018	BUY	$9.65 - $12.65 $176,324 - $231,140	18,272	18,272 $205,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.